JCR Pharmaceuticals Co., Ltd. (JCRRF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
JCR Pharmaceuticals Co., Ltd. (JCRRF) trades at $3.31 with AI Score 48/100 (Grade C). JCR Pharmaceuticals Co. , Ltd. Market cap: $403.80M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for JCRRF: JCRRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates JCRRF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
JCRRF: the 1 perspectives are evenly split.
How is this calculated? →JCR Pharmaceuticals Co., Ltd. (JCRRF) Healthcare & Pipeline Overview
JCR Pharmaceuticals Co., Ltd., established in 1975, is a specialized Japanese pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products, regenerative medicines, and drug substances. It addresses therapeutic areas including growth hormone deficiency, rare genetic disorders, and acute graft-versus-host disease, while actively developing treatments for renal anemia.
What Is the Investment Thesis for JCRRF?
JCR Pharmaceuticals Co., Ltd. presents an investment profile characterized by its established presence in specialized pharmaceutical markets within Japan and a focused pipeline addressing significant medical needs. With a market capitalization of $403.80M and a P/E ratio of 25.25, the company demonstrates profitability with a profit margin of 5.4% and a robust gross margin of 74.6%. A key value driver is its portfolio of therapies for rare diseases and specialized conditions, including GROWJECT for growth hormone deficiency, IZCARGO for Mucopolysaccharidosis type II, and Agalsidase Beta BS for Fabry disease, which often command premium pricing and benefit from limited competition. The ongoing development of Epoetin Alfa BS and Darbepoetin Alfa BS Injections for renal anemia represents a significant growth catalyst, targeting a large patient population and potentially expanding JCR's market reach beyond its current niche. The company's dividend yield of 4.40% also provides income to shareholders. Risks include the inherent uncertainties of pharmaceutical development, regulatory hurdles in Japan, and the competitive landscape for its existing and pipeline products. Its low Beta of 0.13 suggests relatively low volatility compared to the broader market.
Based on FMP financials and quantitative analysis
JCRRF Key Highlights
- Market Capitalization: $0.38 billion, reflecting its valuation as a specialized pharmaceutical entity.
- P/E Ratio: 25.25, indicating investor expectations for future earnings growth relative to its current profitability.
- Gross Margin: 74.6%, demonstrating strong cost control over its core pharmaceutical and regenerative medicine products.
- Profit Margin: 5.4%, showcasing the company's ability to convert revenue into net income after all expenses.
- Dividend Yield: 4.40%, providing a significant return to shareholders through regular distributions.
Who Are JCRRF's Competitors?
JCRRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| GSK GSK plc | $53.09 | -1.06% | 107B | 61 |
| SNYNF Sanofi | $85.25 | +0.64% | $102.48B | 48 |
| GIKLY Grifols, S.A. | $4.77 | -6.47% | $12.54B | 48 |
| CSPCY CSPC Pharmaceutical Group Limited | $4.19 | +9.11% | $12.07B | 48 |
| DPHAY Dechra Pharmaceuticals PLC | $98.00 | +1.98% | $5.58B | 48 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are JCRRF's Key Strengths?
- Established portfolio of specialized pharmaceutical products for rare and critical conditions.
- Integrated capabilities across R&D, manufacturing, and sales within Japan.
- Robust gross margin of 74.6% indicating efficient production and pricing power.
- Active pipeline development targeting significant therapeutic areas like renal anemia.
What Are JCRRF's Weaknesses?
- Geographic concentration primarily in Japan, limiting global market exposure.
- Reliance on a relatively small number of highly specialized products.
- "OTC Other" tier status, which may imply lower liquidity and disclosure compared to major exchanges.
- Unknown disclosure status for OTC market, potentially limiting investor information.
What Could Drive JCRRF Stock Higher?
- Successful clinical trial results and regulatory approval for Epoetin Alfa BS and Darbepoetin Alfa BS Injections for renal anemia, potentially expanding market reach.
- Introduction of new formulations or expanded indications for existing key products like GROWJECT or IZCARGO, driving incremental revenue growth.
- Continued market penetration and adoption of specialized therapies for rare diseases and acute graft-versus-host disease within Japan.
- Strategic partnerships or collaborations that could accelerate pipeline development or facilitate market expansion.
What Are the Key Risks for JCRRF?
- Financial-distress signal — its Altman Z-Score of 1.51 sits in the distress zone (elevated bankruptcy risk).
- Regulatory delays or failure to secure approvals for pipeline products, particularly the renal anemia treatments.
- Intense competition in the specialized pharmaceutical market from larger, more resourced companies.
- Patent expirations on existing key products, leading to increased competition from biosimilars and generic versions.
- Reliance on the Japanese market, exposing the company to specific regional economic and healthcare policy risks.
- Challenges associated with OTC trading, including lower liquidity and limited public disclosure, impacting investor confidence and stock performance.
What Are the Growth Opportunities for JCRRF?
- Expansion in Rare Disease Treatments: JCR Pharmaceuticals has established a strong presence in the rare disease market with products like IZCARGO for Mucopolysaccharidosis type II and Agalsidase Beta BS for Fabry disease. These conditions, while affecting smaller patient populations, often have limited treatment options and command premium pricing, providing stable revenue streams. The ongoing research and development in this area, leveraging existing expertise and infrastructure, could lead to new product introductions or expanded indications. The global orphan drug market is projected to grow significantly, potentially reaching over $300 billion by the early 2030s, offering substantial long-term opportunities for specialized players like JCR within Japan.
- Development and Commercialization of Renal Anemia Treatments: The company's pipeline includes Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both aimed at treating renal anemia. This represents a strategic expansion into a larger patient demographic compared to its current rare disease focus. Renal anemia is a common complication of chronic kidney disease, a condition with increasing prevalence globally, including in Japan. Successful development, regulatory approval, and commercialization of these biosimilar injections could significantly boost JCR's market share in a well-established therapeutic area. The global market for erythropoiesis-stimulating agents (ESAs) for renal anemia is substantial, estimated to be several billion dollars annually, presenting a considerable growth avenue.
- Growth in Growth Hormone Deficiency Market: GROWJECT, JCR's treatment for growth hormone deficiency and short stature, is a key product. Continued market penetration and potential expansion of indications or formulations for growth hormone therapy could drive further revenue growth. The market for human growth hormone is stable and growing, driven by increased diagnosis rates and broader applications beyond pediatric short stature. JCR's established presence and brand recognition in this specific therapeutic area within Japan provide a solid foundation for incremental growth, supported by ongoing medical advancements and patient awareness campaigns over the next 5-10 years.
- Advancements in Regenerative Medicine: JCR Pharmaceuticals is actively involved in regenerative medicines, exemplified by TEMCELL HS Inj for acute graft-versus-host disease. This segment represents a high-growth, innovative frontier in healthcare. Continued investment in R&D for new regenerative medicine therapies or expanding the applications of existing ones could unlock significant future value. The global regenerative medicine market is experiencing rapid expansion, projected to reach hundreds of billions of dollars by the mid-2030s, driven by technological breakthroughs and increasing clinical applications. JCR's early engagement positions it to capitalize on this long-term trend, particularly within the Japanese regulatory framework for regenerative therapies.
- Diversification into Medical Devices and Laboratory Instruments: Beyond its core pharmaceutical and regenerative medicine segments, JCR Pharmaceuticals also provides medical devices and laboratory instruments. This diversification offers a complementary revenue stream and can leverage existing relationships with healthcare providers and research institutions. While specific market sizes for JCR's offerings are not provided, the broader medical device and laboratory equipment markets are robust and growing, driven by technological advancements and increasing healthcare infrastructure investments. Strategic expansion or enhancement of this product line could provide stable, incremental growth and reduce reliance solely on pharmaceutical product cycles over the next 3-5 years.
What Opportunities Does JCRRF Have?
- Successful commercialization of pipeline products for renal anemia, expanding market reach.
- Further expansion into regenerative medicine applications and new rare disease therapies.
- Potential for international partnerships or market entry beyond Japan for specialized products.
- Leveraging expertise in drug substance manufacturing for contract development and manufacturing organization (CDMO) services.
What Threats Does JCRRF Face?
- Intense competition from larger pharmaceutical companies in existing and pipeline therapeutic areas.
- Regulatory changes or delays in drug approvals within Japan.
- Patent expirations on key products leading to biosimilar competition.
- Clinical trial failures or unexpected adverse events for pipeline candidates.
What Are JCRRF's Competitive Advantages?
- Specialized product portfolio addressing niche and rare diseases with high barriers to entry.
- Integrated operations encompassing R&D, manufacturing, and sales within Japan, ensuring quality control and market responsiveness.
- Established brand recognition and clinical trust for existing therapies like GROWJECT and IZCARGO.
- Ongoing pipeline development in areas like renal anemia, potentially creating new market exclusivity.
What Does JCRRF Do?
JCR Pharmaceuticals Co., Ltd., a distinguished specialized pharmaceutical company, traces its origins to 1975 when it was established in Ashiya, Japan. For over five decades, the company has cultivated a comprehensive operational footprint across the entire lifecycle of pharmaceutical products, regenerative medicines, and active drug substances. Its core activities are meticulously integrated within Japan, encompassing robust research and development initiatives, advanced manufacturing capabilities, and the strategic import, export, and sale of its diverse portfolio of medical items. This integrated approach allows JCR Pharmaceuticals to maintain stringent quality control and respond effectively to domestic market needs. The company's current therapeutic offerings are critical for patients facing specific and often severe medical conditions. These include GROWJECT, a vital treatment for individuals suffering from growth hormone deficiency and various forms of short stature, addressing a significant pediatric and adult endocrine need. Another cornerstone product is IZCARGO, specifically engineered to treat Mucopolysaccharidosis type II, a rare genetic lysosomal storage disorder, underscoring JCR's commitment to orphan diseases. Furthermore, Agalsidase Beta BS I.V. Infusion is a key therapy administered for the management of Fabry disease, another complex genetic disorder requiring specialized intervention. TEMCELL HS Inj represents JCR's foray into advanced therapies, employed effectively in the treatment of acute graft-versus-host disease, a severe complication often arising from stem cell transplantation. Beyond its established product lines, JCR Pharmaceuticals is actively expanding its future therapeutic landscape through a focused pipeline. This includes the development of Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both specifically targeted at combating renal anemia, a prevalent condition in patients with chronic kidney disease. In addition to its pharmaceutical and regenerative medicine endeavors, the firm strategically diversifies its revenue streams by providing a selection of medical devices and laboratory instruments, catering to broader healthcare and research needs within the Japanese market. This multifaceted approach positions JCR Pharmaceuticals as a key player in Japan's specialized healthcare sector, balancing established therapies with innovative pipeline development.
What Products and Services Does JCRRF Offer?
- Researches and develops new pharmaceutical products and regenerative medicines.
- Manufactures active drug substances and finished pharmaceutical products.
- Imports and exports a range of medical items within Japan.
- Sells specialized therapeutic products for growth hormone deficiency (GROWJECT).
- Provides treatments for rare genetic disorders like Mucopolysaccharidosis type II (IZCARGO) and Fabry disease (Agalsidase Beta BS I.V. Infusion).
- Offers regenerative medicine for acute graft-versus-host disease (TEMCELL HS Inj).
- Develops pipeline products, including Epoetin Alfa BS and Darbepoetin Alfa BS Injections for renal anemia.
- Distributes medical devices and laboratory instruments.
How Does JCRRF Make Money?
- Develops and commercializes proprietary and biosimilar pharmaceutical products, generating revenue from sales.
- Engages in research and development to create new therapies, with future revenue potential from successful pipeline products.
- Manufactures active drug substances and finished goods, controlling the supply chain for its products.
- Sells medical devices and laboratory instruments, diversifying its revenue streams beyond drug sales.
What Industry Does JCRRF Operate In?
JCR Pharmaceuticals Co., Ltd. operates within the highly specialized and regulated Drug Manufacturers - General industry, specifically focusing on niche therapeutic areas and regenerative medicines within Japan. The broader healthcare sector is characterized by ongoing innovation, an aging global population driving demand for advanced treatments, and increasing R&D expenditures. JCR's positioning in rare diseases (Mucopolysaccharidosis type II, Fabry disease) and specialized conditions (growth hormone deficiency, acute graft-versus-host disease) allows it to target markets with unmet medical needs, often benefiting from orphan drug designations and extended market exclusivity. The competitive landscape in Japan includes both domestic pharmaceutical giants and international players, but JCR differentiates itself through its focused pipeline and expertise in specific therapeutic modalities. The active development of treatments for renal anemia aligns with a significant and growing patient population, reflecting a strategic move into a broader, yet still specialized, market segment within the pharmaceutical industry.
Who Are JCRRF's Key Customers?
- Hospitals and clinics treating patients with growth hormone deficiency.
- Specialized medical centers and rare disease clinics.
- Transplant centers utilizing regenerative medicine for acute graft-versus-host disease.
- Nephrology departments and dialysis centers for future renal anemia treatments.
- Research institutions and laboratories requiring medical devices and instruments.
How JCR Pharmaceuticals Co., Ltd. Is Valued
JCR Pharmaceuticals Co., Ltd. carries a market capitalization of $403.80M, placing it in the small-cap category. Relative to its peer group, JCRRF's quantitative score of 48/100 is below the peer average of 60/100.
Company Profile
JCR Pharmaceuticals Co., Ltd. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Ashiya, JP. The company is led by CEO Toru Ashida. JCRRF has traded publicly since 2021.
ROE 5%Key Financial Metrics
Return on equity for JCR Pharmaceuticals Co., Ltd. stands at 4.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.0%, showing how much profit it generates from its asset base. JCRRF trades at a trailing price-to-earnings ratio of 25.53, above the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
JCR Pharmaceuticals Co., Ltd.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.51 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project JCR Pharmaceuticals Co., Ltd. revenue of about $39.15B for fiscal 2026, with EPS near $10.94. The estimate reflects 6 contributing analysts.
JCRRF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Established portfolio of specialized pharmaceutical products for rare and critical conditions.
- Integrated capabilities across R&D, manufacturing, and sales within Japan.
- Robust gross margin of 74.6% indicating efficient production and pricing power.
- Active pipeline development targeting significant therapeutic areas like renal anemia.
Bear Case
- Geographic concentration primarily in Japan, limiting global market exposure.
- Reliance on a relatively small number of highly specialized products.
- "OTC Other" tier status, which may imply lower liquidity and disclosure compared to major exchanges.
- Unknown disclosure status for OTC market, potentially limiting investor information.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
JCRRF Latest News
No recent news available for JCRRF.
JCRRF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for JCRRF.
Price Targets
Wall Street price target analysis for JCRRF.
JCRRF MoonshotScore
What does this score mean?
The MoonshotScore rates JCRRF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Toru Ashida
Chief Executive Officer
Toru Ashida serves as the Chief Executive Officer of JCR Pharmaceuticals Co., Ltd., overseeing a workforce of 934 employees. His leadership is instrumental in guiding the company's comprehensive operations across research, development, manufacturing, and the commercialization of pharmaceutical products, regenerative medicines, and active drug substances. While specific details of his early career and educational background are not provided, his position at the helm of a specialized pharmaceutical company established in 1975 suggests a profound understanding of the healthcare industry, regulatory landscapes, and the intricacies of drug development and market strategy within Japan.
Track Record: Under Toru Ashida's leadership, JCR Pharmaceuticals has maintained its focus on specialized therapeutic areas, successfully bringing products like GROWJECT, IZCARGO, and TEMCELL HS Inj to market. He has overseen the strategic expansion of the company's pipeline into significant areas such as renal anemia, demonstrating a commitment to addressing unmet medical needs and driving future growth. His management has contributed to the company's robust gross margin of 74.6% and a profit margin of 5.4%.
JCRRF OTC Market Information
JCR Pharmaceuticals Co., Ltd. trades on the "OTC Other" tier of the OTC market. This tier is typically for companies that do not meet the disclosure requirements of higher OTC tiers (like OTCQX or OTCQB) or major exchanges such as the NYSE or NASDAQ. Companies in the "OTC Other" tier may have limited public disclosure, making it more challenging for investors to access comprehensive financial and operational information. Unlike major exchanges with strict listing standards, "OTC Other" has minimal requirements, often leading to less transparency and potentially higher risk for investors due to reduced oversight and reporting obligations.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure due to "Unknown" status, hindering investor due diligence.
- Lower liquidity and wider bid-ask spreads compared to major exchanges, impacting trade execution.
- Increased volatility potential due to smaller trading volumes and fewer market makers.
- Less stringent regulatory oversight than major exchanges, potentially increasing investment risk.
- Difficulty in obtaining reliable, up-to-date financial and operational information.
- Verify the company's official financial statements directly from their investor relations if available.
- Research any available news, press releases, or corporate filings beyond basic OTC listings.
- Assess the company's business fundamentals, product pipeline, and market position independently.
- Evaluate the management team's experience and track record through external sources.
- Understand the specific risks associated with investing in a company with "Unknown" disclosure on "OTC Other" tier.
- Consult with a financial advisor experienced in OTC markets.
- Analyze trading volume and bid-ask spreads over time to gauge liquidity.
- Established in 1975, indicating a long operational history and stability.
- Clear business description with specific pharmaceutical products and pipeline.
- Headquartered in Ashiya, Japan, suggesting a physical presence and operational base.
- Manages 934 employees, indicating a substantial organizational structure.
- Reported financial metrics like Market Cap, P/E, Profit Margin, Gross Margin, and Dividend Yield, suggesting some level of financial reporting.
What Investors Ask About JCR Pharmaceuticals Co., Ltd. (JCRRF) — Healthcare
What does JCR Pharmaceuticals Co., Ltd. do?
JCR Pharmaceuticals Co., Ltd. is a specialized Japanese pharmaceutical company founded in 1975, engaged in the entire lifecycle of pharmaceutical products, regenerative medicines, and active drug substances. Its operations in Japan encompass research, development, manufacturing, import, export, and sale. The company offers key therapeutic products such as GROWJECT for growth hormone deficiency, IZCARGO for Mucopolysaccharidosis type II, Agalsidase Beta BS for Fabry disease, and TEMCELL HS Inj for acute graft-versus-host disease. Additionally, JCR Pharmaceuticals is developing Epoetin Alfa BS and Darbepoetin Alfa BS Injections for renal anemia and sells medical devices and laboratory instruments, positioning itself as a diversified player in specialized healthcare.
What is JCR Pharmaceuticals Co., Ltd.'s strategy for pipeline development?
JCR Pharmaceuticals Co., Ltd.'s pipeline development strategy is focused on addressing significant unmet medical needs, particularly evident in its active development of Epoetin Alfa BS and Darbepoetin Alfa BS Injections. These biosimilar products are specifically designed for the treatment of renal anemia, a prevalent condition associated with chronic kidney disease. This strategic move indicates an intent to expand beyond its current niche in rare diseases and specialized conditions into a broader, yet still specialized, therapeutic area with a large patient population. The company leverages its established R&D and manufacturing capabilities to advance these candidates through clinical development, aiming for successful regulatory approval and subsequent commercialization within the Japanese market.
What are the main risks for JCRRF?
JCRRF faces several key risks inherent to the pharmaceutical industry and its OTC market listing. Potential risks include regulatory delays or outright failure in securing approvals for its pipeline products, such as the renal anemia treatments, which could significantly impact future revenue streams. The company operates in a competitive landscape, facing ongoing pressure from larger pharmaceutical entities in both its existing specialized markets and new therapeutic areas. Furthermore, the potential for patent expirations on its current key products could lead to increased competition from biosimilars. Its primary geographic focus on Japan exposes it to specific regional economic and healthcare policy shifts. Lastly, as an "OTC Other" listed stock with "Unknown" disclosure, JCRRF presents risks related to lower liquidity, wider bid-ask spreads, and limited public financial information, which can affect investor confidence and trading dynamics.
How does JCR Pharmaceuticals Co., Ltd. manage patent expiration risks?
While specific details on JCR Pharmaceuticals Co., Ltd.'s patent expiration management strategies are not provided in the source data, pharmaceutical companies typically employ several approaches. These include continuous investment in research and development to introduce new, innovative products or expand indications for existing ones, thereby diversifying the revenue base before patents expire. Developing biosimilars, as seen with their renal anemia pipeline (Epoetin Alfa BS and Darbepoetin Alfa BS Injections), is another strategy to leverage existing market demand for off-patent biologics. Additionally, lifecycle management strategies, such as developing new formulations, delivery methods, or combination therapies for existing drugs, can extend product viability and market exclusivity, mitigating the impact of impending patent cliffs.
What is JCR Pharmaceuticals Co., Ltd.'s geographic market focus?
JCR Pharmaceuticals Co., Ltd. maintains a primary geographic market focus within Japan. Its comprehensive activities, including research, development, manufacturing, import, export, and sale of pharmaceutical products, regenerative medicines, and active drug substances, are explicitly stated as being conducted "in Japan." This localized operational model allows the company to concentrate its resources and expertise on meeting the specific healthcare needs and navigating the regulatory environment of the Japanese market. While the company engages in import and export, its core commercialization and strategic initiatives appear to be centered domestically, serving Japanese patients and healthcare providers with its specialized therapeutic offerings and medical instruments.
What are the key factors to evaluate for JCRRF?
JCR Pharmaceuticals Co., Ltd. (JCRRF) holds an AI score of 48/100 (low). Not financial advice.
How frequently does JCRRF data refresh on this page?
JCRRF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven JCRRF's recent stock price performance?
JCR Pharmaceuticals Co., Ltd. (JCRRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established portfolio of specialized pharmaceutical products for rare and critical conditions. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.